Trimebutine as a modulator of gastrointestinal motility
- 464 Downloads
Trimebutine has been used for treatment of both hypermotility and hypomotility disorders of the gastrointestinal (GI) tract, such as irritable bowel syndrome. In this issue, Tan et al. (2011) examined the concentration-dependent dual effects of trimebutine on colonic motility in guinea pig. The authors suggested that trimebutine attenuated colonic motility mainly through the inhibition of L-type Ca2+ channels at higher concentrations, whereas, at lower concentrations, it depolarized membrane potentials by reducing BKca currents, resulting in the enhancement of the muscle contractions. Trimebutine might be a plausible modulator of GI motility, which gives an insight in developing new prokinetic agents. Further studies to elucidate the effects of trimebutine on the interstitial cells of Cajal, the pacemaker in GI muscles would promote the therapeutic benefits as a GI modulator.
KeywordsIrritable Bowel Syndrome Interstitial Cell Tegaserod Colonic Motility Trimebutine
Unable to display preview. Download preview PDF.
- Hwang, S. J., Blair, P. J., Britton, F. C., O’Driscoll, K. E., Hennig, G., Bayguinov, Y. R., Rock, J. R., Harfe, B. D., Sanders, K. M., and Ward, S. M., Expression of anoctamin1/TMEM16A by interstitial cells of Cajal is fundamental for slow wave activity in gastrointestinal muscles. J. Physiol., 587, 4887–4904 (2009).PubMedCrossRefGoogle Scholar
- Mearin, F., Badía, X., Balboa, A., Baró, E., Caldwell, E., Cucala, M., Díaz-Rubio, M., Fueyo, A., Ponce, J., Roset, M., and Talley, N. J., Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. Scand. J. Gastroenterol., 36, 1155–1161 (2001).PubMedCrossRefGoogle Scholar